TOKYO, June 25, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and ALBERT Inc, (Mothers: 3906) jointly developed a data scientist training program for the pharmaceutical industry. The training program is part of CHUGAI DIGITAL ACADEMY, a digital talent training initiative started in April 2021, and aims to promote DX through the acquisition of data utilization skills including pharmaceutical-specific elements. It has been launched for Chugai Group employees in June 2021.
■Promoting the development of DX-leading employees in the pharmaceutical industry
In the healthcare industry, data analysis and AI are expected to be utilized in various fields, including preventive medicine and diagnostic support, personalized medicine, drug development, and extension of healthy life expectancy. In order to cope with the situation, it is important for companies to develop digital talents with specialized skills in analysis technology and statistics, as well as pharmaceutical industry-specific skills.
Chugai has set “Strengthen the digital platform” as one of the basic strategies of CHUGAI DIGITAL VISION 2030, and started CHUGAI DIGITAL ACADEMY in April 2021, a structured initiative for digital talent development. The project aims not only to strengthen the development of in-house digital talents, but also to strengthen our recruitment capabilities, promote collaboration with external parties, and form an ecosystem, by returning profits to society.
ALBERT, with over 250 data scientists, has provided each industry with a more practical program, Data Scientist Training Support, by utilizing the expertise cultivated through in-house human resource training and having active data scientists as instructors. In addition, ALBERT has been working to develop industry-specific development programs.
This time, Chugai and ALBERT have jointly developed a data scientist training program specialized for the pharmaceutical industry. With the support of ALBERT, which has strengths in the development of data scientists, Chugai will strengthen the development of digital talents to promote DX.
[Data scientist development program for the pharmaceutical industry]
In addition to basic statistical analyses and programming techniques required to data scientists, this program enables the acquisition of knowledge and skills for data utilization specific to the pharmaceutical industry, such as clinical statistics and epidemiology fundamentals.
■Satoko Shisai, Chugai’s Vice President, Head of Digital & IT Supervisory Division
In the healthcare industry, the development of digital talents capable of analyzing data and utilizing AI is an important issue. We are very pleased to develop a data scientist training program for the pharmaceutical industry in cooperation with ALBERT, an expert in data science. Under CHUGAI DIGITAL VISION 2030, Chugai started CHUGAI DIGITAL ACADEMY, a structured initiative for digital talent development, in April 2021 to strengthen the development of digital talents and returning the knowledge and skills to society. We will continue to promote collaboration with various external partners and contribute to strengthening of digital talents throughout the industry.
■Takeshi Matsumoto, ALBERT’s President
As one of the leading data science companies in Japan, ALBERT has contributed to society through the development of AI implemented in industry and the training of data scientists. The data scientist training expertise that ALBERT has accumulated since its establishment can be utilized in the development of digital talents, which forms the base of CHUGAI DIGITAL VISION 2030, to acquire advanced data analysis techniques. In particular, we are confident that the industry-specific programs, including the unique elements of the pharmaceutical industry that we have developed this time, will contribute to the training of professional human resources who will lead the pharmaceutical industry with advanced and strategic healthcare solutions, and further accelerate DX promotion.
ALBERT will continue to work on strengthening the digital talent base of Chugai Group. At the same time, looking at the possibility of external provision of the jointly developed program, we aim to create a platform that can be widely used by people aspiring to promote DX in the pharmaceutical industry through collaboration with external communities and personnel exchanges
■Chugai Pharmaceutical Co., Ltd.
Head office: 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo
Establishment: March 8, 1943
Representative: Osamu Okuda, President & CEO
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Principal lines of business: Research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals
Head office:21-1, Kita-Shinjuku 2-chome, Shinjuku-ku, Tokyo
Establishment: July 1, 2005
Representative: Takeshi Matsumoto, President
Code number: 3906 (Mothers of Tokyo Stock Exchange)
Principal lines of business: Data Solution Business：consultation for implementing AI, big data analysis, AI algorithm development and systems development/operation, provision of original AI-based products, and data scientist training support
[Contact Information on the Press Release]
Corporate Communications Dept.
Chugai Pharmaceutical Co., Ltd.
Contact from the press
Media Relations Group
Contact from analysts/investors
Investor Relations Group
■Suzuki, Management Strategy Department
TEL: +81-3-5937-1389 MAIL: email@example.com